Revelation Biosciences
program highlights us licensed from additional related applications anticipated next step large market potential approximately of associated infection annual deaths | Revelation Biosciences
Company
Deck Type
Sector
Industry
Deck date
October 2022
Slide
6 of 18
Related slides by other companies
Nuvalent
Investor Presentation
January 2024
track record of success resource efficient execution and value creation across an expanding portfolio wholly owned programs emergence from first clinical proof of concept second proof of concept first pivotal study disclosed parallel lead programs initiated two global phase studies demonstrated clinical proof of concept and alk for alk program presented preclinical profiles demonstrated clinical proof of concept initiated phase with supporting desired target product for program registrational intent disclosed third novel program advanced her program towards listed her ended with approximately in cash cash equivalents and marketable securities unaudited with potential to deliver multiple transformative catalysts within cash runway window into preliminary unaudited estimate only as the date this presentation subject to change following completion year end closing procedures does not present all information necessary for an understanding financial position as a | Nuvalent
Cheesecake Factory
Investor Presentation
November 2024
underlying key assumptions | Cheesecake Factory
Cheesecake Factory
Investor Presentation
February 2025
underlying key assumptions | Cheesecake Factory
Cheesecake Factory
Investor Presentation
October 2024
underlying key assumptions | Cheesecake Factory
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights